Nano cap Chimerix (NASDAQ:CMRX) jumps 41% premarket on robust volume in reaction to the initiation of a Phase 2/3 clinical trial evaluating dociparstat sodium (DSTAT) in COVID-19 patients with acute lung injury.
The Phase 2 part of the study will enroll 24
subjects to confirm the maximum safe dose while the Phase 3 part will
enroll ~450 participants.
The primary endpoint will be the proportion of patients who survive and do not require mechanical ventilation through day 28.
The company says DSTAT is a glycosaminoglycan
derivative of blood thinner heparin with robust anti-inflammatory
properties, including the potential to address underlying causes of
coagulation disorders with substantially reduced risk of bleeding
complications compared to commercially available forms of heparin.
Management will host a conference call this morning at 8:30 am ET to discuss the trial.
https://seekingalpha.com/news/3565937-chimerix-up-41-premarket-on-launch-of-dstat-study-in-covidminus-19
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.